The U.S. Food and Drug Administration (FDA) has cleared Onvision, a needle tip tracking technology for use with ultrasound-guided anesthesia procedures that was developed B. Braun and Royal Philips, the parent company of Philips Healthcare.
The FDA gave 510(k) clearance to Onvision, a real-time needle guidance tool for use on the latest version of Xperius, an ultrasound system developed by B. Braun and Philips designed to guide anesthesia procedures. Onvision works with the Stimuplex Onvision needle.
Onvision aims to help anesthesiologists accurately position the needle tip inside the body for peripheral nerve blocks.
